Status:
COMPLETED
Omega-3/Omega-6 Fatty Acids for Attention-Deficit/Hyperactivity Disorder (ADHD): A Trial in Children and Adolescents
Lead Sponsor:
Göteborg University
Collaborating Sponsors:
Vifor Pharma
Conditions:
ADHD
Reading/Writing Disorder
Eligibility:
All Genders
8-18 years
Phase:
PHASE3
Brief Summary
Objective: To assess whether supplementation with Omega 3/6 fatty acids (eye q®) was effective in the treatment of ADHD and its diagnostic subtypes and comorbid conditions, in children and adolescents...
Detailed Description
The study design is a randomised, double-blind placebo-controlled trial with a total duration of 6 months. 50-100 children and adolescents, aged 8-18 years, who meet the DSM-IVÔ criteria for Attention...
Eligibility Criteria
Inclusion
- Patients aged 8-18 years
- Met DSM-IV criteria for a diagnosis of ADHD of any subtype
Exclusion
- Autism
- Psychosis
- Bipolar disorder
- Mental retardation
- Uncontrolled seizure disorder
- Hyper- or hypothyroidism
- Significant other medical conditions
- Weight below 20 kg
- Alcohol or drug abuse or the use in the past three months of any psychoactive drugs or Omega 3 preparations
Key Trial Info
Start Date :
August 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2007
Estimated Enrollment :
82 Patients enrolled
Trial Details
Trial ID
NCT01219309
Start Date
August 1 2004
End Date
April 1 2007
Last Update
October 13 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.